Antithrombin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Usage (Therapeutics, Diagnostics, Research, Others), By Source (Human, Recombinant Goat Milk, Others), By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs), By Region and Competition, 2020-2030F

Market Overview

Global Antithrombin Market was valued at USD 782.03 Million in 2024 and is expected to reach USD 1066.23 Million by 2030 with a CAGR of 5.26% during the forecast period. The global antithrombin market encompasses the pharmaceutical and biotechnology industry's efforts to produce and distribute antithrombin products. Antithrombin is a naturally occurring protein in the blood that plays a crucial role in preventing excessive blood clotting. Dysfunctional antithrombin levels can lead to thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). Therefore, antithrombin products are used to treat and prevent these conditions.

Key Market Drivers

Increasing Prevalence of Thrombotic Disorders

Thrombotic disorders, characterized by the formation of dangerous blood clots within the circulatory system, pose a significant threat to public health worldwide. As the incidence of these disorders continues to climb, so does the demand for effective treatments. Among these treatments, antithrombin products are emerging as a crucial player, playing a vital role in preventing and managing thrombotic events.

Thrombotic disorders encompass a range of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and disseminated intravascular coagulation (DIC). These disorders can lead to life-threatening complications, including organ damage and death. The World Health Organization (WHO) identifies thrombosis as a major contributor to global morbidity and mortality. According to Centers for Disease Control and Prevention, each year, venous thromboembolism (VTE), a condition involving blood clots, affects up to 900,000 individuals in the United States. People are especially vulnerable to VTE during or shortly after hospitalization, whether or not they undergo surgery, while receiving cancer treatment, or during the pregnancy period and its immediate aftermath. It is estimated that VTE causes 60,000 to 100,000 deaths annually in the U.S., with many others experiencing long-term complications due to the condition. These figures highlight the significant health burden of VTE, emphasizing the need for effective prevention and treatment strategies to mitigate the associated risks.

As the global population ages, the risk of thrombotic events increases. Advanced age is a significant risk factor for thrombosis due to changes in the vascular system and decreased mobility. Modern sedentary lifestyles, characterized by prolonged sitting and limited physical activity, are associated with an increased risk of thrombotic events, especially DVT. Obesity is a known risk factor for thrombosis, as it leads to inflammation and other metabolic changes that promote clot formation. Conditions such as diabetes, cancer, and cardiovascular disease can increase the risk of thrombotic events. Some individuals inherit genetic factors that make them more susceptible to thrombosis. Major surgeries, including orthopedic, cardiovascular, and gynecological procedures, carry a heightened risk of blood clots. Antithrombin products are often used prophylactically in these situations.

Antithrombin is a natural protein found in the bloodstream that regulates the clotting process. It works by inhibiting several clotting factors, including thrombin and factor Xa. When antithrombin levels are deficient or dysfunctional, the risk of clot formation increases significantly.

The growing number of individuals affected by thrombotic disorders necessitates a greater demand for antithrombin products. These products are essential for preventing and treating clot-related complications. Antithrombin products are used prophylactically in high-risk situations, such as before and after surgery, to prevent clot formation. As surgical procedures become more common, the demand for antithrombin therapy rises accordingly. Patients who experience thrombotic events often require therapeutic antithrombin treatment to dissolve existing clots and prevent further complications. The increasing prevalence of thrombotic disorders has spurred research and development efforts to create more effective antithrombin therapies, including recombinant products and novel formulations.

Aging Population Disorders

The world's population is aging at an unprecedented rate, with a significant impact on healthcare systems globally. As people age, they become increasingly vulnerable to various health conditions, including thrombotic disorders, which involve the formation of blood clots within blood vessels. This demographic shift towards an older population is a powerful driver behind the growth of the global antithrombin market.

The aging of the global population is a well-documented phenomenon. Advances in healthcare, improved living conditions, and better access to medical care have led to longer life expectancies. As a result, the world is witnessing a significant increase in the number of older adults, particularly those aged 65 and older. This demographic shift has profound implications for healthcare, including an increased prevalence of age-related health conditions. According to Centers for Disease Control and Prevention, each year, venous thromboembolism (VTE), a condition involving blood clots, affects up to 900,000 individuals in the United States. People are especially vulnerable to VTE during or shortly after hospitalization, whether or not they undergo surgery, while receiving cancer treatment, or during the pregnancy period and its immediate aftermath. It is estimated that VTE causes 60,000 to 100,000 deaths annually in the U.S., with many others experiencing long-term complications due to the condition. These figures highlight the significant health burden of VTE, emphasizing the need for effective prevention and treatment strategies to mitigate the associated risks.

Aging leads to changes in the coagulation and fibrinolysis pathways, making older individuals more susceptible to clot formation. Age-related chronic conditions like cardiovascular disease, diabetes, and cancer increase the risk of thrombosis. Older adults often have decreased mobility, which can lead to the stagnation of blood flow and an increased risk of clot formation. Older adults may undergo surgical procedures, which can be associated with a higher risk of post-operative thrombosis.

As the population ages, the number of individuals at risk of thrombotic disorders rises. This results in a greater demand for antithrombin products for both prophylactic and therapeutic use.  Older individuals may require surgery for various medical conditions. These surgeries often necessitate the use of antithrombin products to prevent post-operative clot formation. Antithrombin therapy becomes crucial in managing thrombotic complications associated with age-related chronic illnesses, such as cardiovascular diseases. The growing demand for antithrombin products has incentivized pharmaceutical and biotechnology companies to invest in research and development. This has led to innovations in antithrombin therapies, including recombinant products and improved formulations.

Advancements in Biotechnology and Pharmaceuticals

The global antithrombin market is experiencing a transformative period, with advancements in biotechnology and pharmaceuticals playing a pivotal role in its growth. Antithrombin, a crucial protein in regulating blood clotting, has seen significant improvements in production techniques, safety, and efficacy, which are driving its increasing relevance in the healthcare sector.

Biotechnology has enabled the development of recombinant antithrombin products. These are produced using genetically engineered cells, which offer a controlled and consistent source of antithrombin, reducing the risk of contamination and supply shortages. Innovative purification methods have been developed to extract antithrombin from human plasma more effectively. These techniques yield highly purified antithrombin concentrates with minimal impurities, enhancing safety and efficacy. Biotechnology has allowed for the development of novel antithrombin formulations, including stable liquid preparations, which offer convenience and ease of administration for patients and healthcare providers.

Research has led to a deeper understanding of the mechanisms behind thrombotic disorders, enabling the development of more targeted antithrombin therapies. These therapies have shown enhanced efficacy in specific patient populations. Long acting antithrombin products have been developed, reducing the frequency of administration for patients. This not only improves patient compliance but also reduces the burden on healthcare systems. Ongoing research has led to the development of antithrombin products with improved safety profiles, reducing the risk of adverse events and allergic reactions.

As antithrombin products become more effective and accessible, the demand for these therapies has grown, especially among individuals at risk of thrombotic disorders. Advancements have expanded the range of indications for antithrombin therapy, leading to its use in various clinical scenarios, including perioperative settings, pregnancy-related complications, and treatment-resistant thrombotic events. Improved manufacturing processes and formulation stability have enabled the global distribution of antithrombin products, making them more readily available to patients in different regions.

Surgical Procedures and Medical Conditions

The global antithrombin market is witnessing significant growth, driven in large part by the increasing prevalence of surgical procedures and medical conditions that heighten the risk of thrombosis. Antithrombin, a vital natural protein in the body's clotting regulation system, has emerged as a critical element in preventing blood clots during surgeries and managing thrombotic complications related to various medical conditions.

Patients undergoing surgery are often immobile for extended periods during and after the procedure, increasing the likelihood of blood stasis and clot formation. Surgical trauma can damage blood vessels, initiating the clotting process as part of the body's natural response to injury. Anesthesia can affect blood flow, further increasing the risk of clot formation. Longer surgeries carry a higher risk of clot formation due to extended periods of immobility. Patients with preexisting medical conditions, such as cancer or cardiovascular disease, are at an elevated risk of thrombotic complications during surgery.

Antithrombin products are administered prophylactically to surgical patients to reduce the risk of postoperative blood clot formation. In certain high-risk surgeries, antithrombin may be used intraoperatively to mitigate the risk of clot formation during the procedure.

Patients with conditions like atrial fibrillation or coronary artery disease are at a higher risk of stroke and heart attack, which may necessitate antithrombin therapy. Cancer patients have an elevated risk of developing venous thromboembolism (VTE), which includes DVT and PE. Antithrombin therapy is often part of VTE management. Conditions like preeclampsia and eclampsia can lead to dangerous clotting events during pregnancy. Antithrombin products may be used in the treatment of these conditions. Some autoimmune diseases, such as antiphospholipid syndrome, can increase the risk of thrombosis, warranting antithrombin therapy.

The rising number of surgical procedures and the growing incidence of medical conditions associated with thrombosis have led to an expanded market for antithrombin products. The use of antithrombin therapy is no longer limited to just a few conditions; it has broadened to encompass a wide range of clinical scenarios. Advances in manufacturing and distribution have improved patient accessibility to antithrombin products, ensuring that they are readily available when needed.

Download Free Sample Report

Key Market Challenges

Limited Awareness and Diagnosis

A significant challenge in the antithrombin market is the lack of widespread awareness regarding thrombotic disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These conditions often present with subtle or non-specific symptoms, and many individuals are unaware of the risk factors associated with them. The lack of knowledge about these disorders means that people may not seek timely medical attention, leading to a delay in diagnosis and treatment. For instance, common symptoms like leg pain, swelling, or difficulty breathing may be overlooked or attributed to less serious conditions. This lack of awareness can significantly reduce the demand for antithrombin therapies, as early intervention is key to effective management and prevention of complications associated with thrombotic disorders. Without timely treatment, patients may face severe health consequences, further diminishing the likelihood of receiving appropriate care. Therefore, raising awareness about these disorders, their symptoms, and the importance of early diagnosis is crucial in ensuring timely treatment and improving the market for antithrombin therapies.

Variability in Diagnosis and Treatment Practices

Thrombotic disorders, such as DVT and PE, can manifest in various ways, with symptoms differing significantly from one patient to another. This variability in how these conditions present itself makes diagnosis a complex task for healthcare providers. In some cases, symptoms may be vague, leading to misdiagnosis or delayed diagnosis. Additionally, risk factors for thrombotic events, including genetics, lifestyle factors, and pre-existing health conditions, can complicate the identification of at-risk patients. This variability is further exacerbated by the inconsistency in diagnostic practices across healthcare providers. Some healthcare professionals may rely on different tests, and diagnostic methods can vary in accuracy, making it difficult to arrive at a timely and correct diagnosis.

Furthermore, variability in treatment practices adds another layer of complexity. Different healthcare providers may have differing opinions on the best approach to treat thrombotic disorders, leading to inconsistent use of antithrombin therapies. Some may opt for alternative treatments based on their expertise or availability, resulting in suboptimal use of antithrombin products. Moreover, treatment protocols are not always standardized, and differences in clinical guidelines across regions or institutions can contribute to the inconsistent use of antithrombin therapies.

Key Market Trends

Novel Therapeutic Indications

Historically, antithrombin therapies have been primarily linked to the management of thrombotic disorders, including conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). However, ongoing research and clinical trials are increasingly expanding the therapeutic applications of these treatments. Antithrombin therapies are now being investigated for their potential benefits in treating a variety of non-thrombotic conditions. For instance, researchers are exploring the use of antithrombin products in sepsis, a severe body-wide response to infection, where blood clotting plays a key role in the pathogenesis of organ failure. By targeting this coagulation pathway, antithrombin therapies may help manage sepsis-induced coagulopathy and improve patient outcomes. In February 2022, Grifols initiated a partnership with Endpoint Health, Inc. aimed at jointly advancing and bringing to market a therapy for Sepsis utilizing Antithrombin III (AT-III). Under this collaboration, Grifols will leverage its extensive industry know-how in plasma-protein therapies and serve as the exclusive provider of AT-III, a vital plasma protein used in the treatment of individuals with blood clotting disorders.

In addition to sepsis, antithrombin therapies are being studied in the context of liver diseases, including cirrhosis and acute liver failure. The role of blood clotting factors in liver disease progression has garnered attention, suggesting that antithrombin products could help mitigate the hypercoagulable states seen in such conditions. Furthermore, antithrombin therapies are also being explored as adjuncts to cancer treatments. Tumors can cause alterations in the coagulation system, and antithrombin may help reduce the risk of thrombotic events, which are common in cancer patients. This broadening of therapeutic indications could potentially open new market opportunities, leading to an increase in the demand for antithrombin products beyond their traditional use in thrombotic disorders. As these novel therapeutic applications gain traction, they hold the promise of improving outcomes for patients suffering from a wider range of complex, life-threatening conditions.

Enhanced Formulations and Drug Delivery

In addition to expanding therapeutic indications, advancements in drug formulation and delivery systems are revolutionizing the antithrombin market. Traditional antithrombin therapies typically require frequent injections or infusions, which can be burdensome for patients and lead to issues with adherence. However, innovations in long-acting formulations are addressing these challenges. Extended-release antithrombin products are being developed to have longer half-lives, allowing for less frequent dosing. This improvement not only increases patient convenience but also enhances compliance, as patients no longer need to administer therapy as often, making it easier to manage their treatment schedules. In the same month of February 2022, Techdow USA Inc., a fully integrated manufacturer of generic injectable medications, successfully introduced its Heparin Sodium Injection, USP, to the United States market. 

The development of more efficient and patient-friendly drug delivery methods, such as subcutaneous injections or self-administered devices, is also improving the accessibility and ease of use of antithrombin therapies. These innovations empower patients to take control of their treatment, reducing the need for frequent hospital visits or reliance on healthcare providers for administration. Moreover, advancements in the stability of antithrombin formulations, including temperature-stable versions, are expanding the geographic accessibility of these therapies. By improving the shelf-life and ease of distribution of antithrombin products, pharmaceutical companies can reach a broader patient base, even in areas with limited healthcare infrastructure.

Overall, these developments in drug formulations and delivery systems are expected to drive market growth by making antithrombin therapies more convenient, less invasive, and more accessible for patients. As patient compliance and convenience improve, the therapeutic potential of antithrombin products will be realized to its full extent, helping to address a wider array of medical needs. The combination of expanding indications and improved formulations is paving the way for a more comprehensive, efficient, and patient-centric antithrombin market.

Segmental Insights

Type Insights

Thrombolytic drugs waspoised for substantial growth in the Global Antithrombin Market during the forecast years for several compelling reasons. Firstly, ongoing advancements in medical research and technology have led to a deeper understanding of thrombotic disorders and their treatment options. This increased knowledge is likely to result in a greater utilization of thrombolytic drugs as a crucial component in the management of various thrombotic conditions, thereby driving their demand. Secondly, the rising prevalence of cardiovascular diseases and other conditions associated with abnormal blood clot formation underscores the need for effective thrombolytic therapies. As the global population ages and lifestyles evolve, the demand for these drugs is expected to surge. Additionally, regulatory approvals and endorsements from healthcare authorities for thrombolytic agents are anticipated to provide a significant boost to their market presence. Altogether, these factors are expected to fuel the growth of thrombolytic drugs in the Global Antithrombin Market during the forecast years.

Download Free Sample Report

Regional Insights

In the forthcoming forecast period, the Asia-Pacific region was poised to experience rapid growth. This upswing can be attributed to the burgeoning adoption of innovative medical treatments and techniques in developing nations like India and China, aimed at combatting a spectrum of diseases. The escalating disposable incomes in these emerging economies, coupled with their heightened capacity to invest in advanced healthcare solutions, create fertile ground for market opportunities in the Asia-Pacific region. Moreover, the increasing burden of an aging population, along with a rising incidence of thrombosis-related ailments and ongoing research into antithrombin deficiency within the region, is expected to be a driving force behind market growth throughout the forecast period.

Notably, the expanding elderly population in India plays a pivotal role in propelling the market in this region. According to data from the NSO, the proportion of elderly individuals in India was projected to reach 10.1% in 2021 and is forecasted to rise to 13.1% by 2031. With this demographic shift, the risk of thrombosis increases substantially, resulting in a heightened demand for antithrombin treatments, which, in turn, stimulates market growth.

Ongoing studies focusing on antithrombin deficiency within the region are anticipated to bolster the availability and utilization of antithrombin products, further augmenting market expansion. For instance, a study published in Frontiers in Neurology in June 2022 highlighted the various causes of antithrombin deficiency, including inherited variants in the SERPINC1 gene. Consequently, diagnostic products such as the SERPINC1 gene test are expected to gain traction, especially in identifying the underlying causes of antithrombin deficiency-related arterial thrombosis, such as ischemic stroke. These new research endeavors pertaining to antithrombin deficiency are thus poised to boost the utilization of specific diagnostic products and contribute to market growth over the forecast period.

Recent Developments

• In June 2024, Sanofi showcased new findings from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), scheduled for June 22-26, 2024, in Bangkok, Thailand. Key presentations will feature ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], including long-term interim phase 3 data highlighting the treatment's efficacy and safety in both adults and children with severe hemophilia A. Additionally, abstracts on fitusiran will provide insights into surgical experience and long-term safety data from the ATLAS phase 3 clinical development program, which includes adults and adolescents with hemophilia A or B, irrespective of inhibitor status.
• In July 2024, A professor from the University of Cincinnati spoke with TCTMD about the RAISE trial, which suggests that the drug reteplase may be a safe and effective treatment for acute ischemic stroke. Similar to tenecteplase and alteplase, reteplase is a clot-busting medication, administered to patients within 4.5 hours of stroke onset in the trial. The results showed that reteplase led to a higher rate of excellent functional outcomes compared to standard alteplase, with no significant increase in symptomatic intracranial hemorrhage, other bleeding complications, or mortality.
• In September 2024, Thrombolytic Science (TSI)  received approval from the US Food and Drug Administration (FDA) regarding its Investigational New Drug application. Said application relates to the clinical-stage biotech company’s mutant for prourokinase (mproUK), a recombinant fibrinolytic pro-enzyme. This reconfirms the safety and tolerability of TSI’s mproUK in healthy volunteers.
• In June 2024, Ethypharm reached an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), for distribution in Europe. Known for its specialization in essential drugs for central nervous system disorders, including severe pain and addiction, as well as hospital injectables, Ethypharm seeks to strengthen its established European pharmaceutical presence through internal development, licensing, and acquisitions. Argatroban, initially approved by MTPC in Sweden in 2004, is now available in 13 European countries, including Germany, the UK, France, Spain, and Italy, as a treatment for heparin-induced thrombocytopenia (HIT) type II. HIT type II is a severe condition with the potential for fatal thromboembolic complications. As an anticoagulant with a short half-life and liver metabolism, Argatroban is particularly suited for post-surgery patients and those with kidney disease who may develop HIT type II.

Key Market Players

• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion S.p.A

Report Scope:

In this report, the Global Antithrombin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Antithrombin Market, By Usage:

o   Therapeutics

o   Diagnostics

o   Research

o   Others

• Antithrombin Market, By Source:

o   Human

o   Recombinant Goat Milk

o   Others

• Antithrombin Market, By Type:

o   Anticoagulant

o   Antiplatelet

o   Thrombolytic Drugs

• Antithrombin Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin Market.

Available Customizations:

Global Antithrombin market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Antithrombin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]